When We Talks

Zymeworks and Jazz Pharmaceuticals ink $50M deal with potential for more – GeekWire


Zymeworks signed a deal with Jazz Pharmaceuticals to develop and commercialize Zymeworks’ lead drug candidate, zanidatamab, which targets the cancer marker HER2.

Zymeworks will receive an upfront payment of $50 million and a second payment of $325 million, at Jazz’s option, following the release of topline data from an ongoing clinical trial. That trial is testing the agent as a second-line treatment for HER2-positive biliary tract cancer; zanidatamab is also being tested against other tumor types in separate studies.

Zymeworks may also receive further payments on completion of future regulatory and commercial milestones, bringing the total value of the deal up to $1.76 billion, plus royalties on sales. Vancouver, B.C.-based Zymeworks has 86 employees working in R&D in Seattle.


Source link

Related posts

This tech-fueled service will provide bus transportation for Seattle Public Schools – GeekWire

Effie Weber

Amazon reportedly eyeing Signify Health as it continues push into healthcare – GeekWire

Effie Weber

Apptio acquires cloud spend optimization startup Cloudwiry – GeekWire

Effie Weber